Today's Elliott Wave analysis provides an update on the Australian Stock Exchange (ASX) focusing on CSL LIMITED (CSL). There is significant upside potential in the third wave of ASX:CSL. This analysis ...

While otherwise robust, CSL half-year results last Wednesday revealed the impact of an “alarming” fall off in influenza ...

CSL (ASX:CSL) has posted its half-year results, delivering results that are best described as mixed. At the headline level, ...

The ASX-listed giant says it can switch manufacturing sites if Donald Trump imposes tariffs on pharmaceuticals. It expects ...

CSL Seqirus, the vaccination segment, was affected by low influenza vaccination rates in the US, dragging down overall ...

The CSL Ltd (ASX: CSL) share price will be watched closely today after the biotech giant released its half year ...

Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business.

These three premier ASX healthcare stocks just reported half-yearly earnings – and each saw its share price dip…So, is now the time to buy?

Sharemarket seesaws; CSL tumbles on sales blow; gold buoys Evolution, De Grey; impairment hit for Ramsay; upgrades on the ...

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

Staff from the City of Côte St. Luc are set to meet with their officials from Côte des Neiges-NDG very soon regarding traffic ...

CSL’s vaccine division is suffering as Americans turn away from flu vaccinations, with a “very severe” influenza season ...